PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7.06%
Positive EBIT growth while Biotechnology median is negative. Peter Lynch might see a strong competitive advantage in operations.
7.06%
Positive operating income growth while Biotechnology is negative. Peter Lynch would spot a big relative advantage here.
10.36%
Positive net income growth while Biotechnology median is negative. Peter Lynch would view this as a notable competitive advantage.
28.30%
EPS growth exceeding 1.5x Biotechnology median of 0.10%. Joel Greenblatt would confirm if consistent earnings expansion underpins these gains.
28.30%
Diluted EPS growth exceeding 1.5x Biotechnology median of 0.10%. Joel Greenblatt would confirm if strong net income growth or buybacks drive outperformance.
24.68%
Share growth above Biotechnology median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
24.68%
Diluted share growth above 2x Biotechnology median. Jim Chanos would suspect undue issuance or heavy employee stock compensation.
No Data
No Data available this quarter, please select a different quarter.
17.79%
OCF growth of 17.79% while Biotechnology is zero. Walter Schloss might see a modest positive difference, which can compound over time.
17.79%
FCF growth of 17.79% while Biotechnology median is zero. Walter Schloss might see a slight edge that could compound over time.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-19298.96%
Negative 10Y OCF/share CAGR while Biotechnology median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-3628.66%
Negative 5Y OCF/share CAGR while Biotechnology median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
45.61%
3Y OCF/share growth of 45.61% while Biotechnology median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
-15204.15%
Negative 10Y net income/share CAGR vs. Biotechnology median of 0.00%. Seth Klarman might see a fundamental problem if peers maintain growth.
97.68%
Net income/share CAGR of 97.68% while Biotechnology median is zero. Walter Schloss might see a modest advantage that can expand mid-term.
59.13%
3Y net income/share CAGR of 59.13% while Biotechnology median is zero. Walter Schloss might see a small advantage that can be scaled further.
9892.41%
Equity/share CAGR of 9892.41% while Biotechnology median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
293.35%
5Y equity/share CAGR of 293.35% while Biotechnology median is zero. Walter Schloss sees a slight positive that might compound if management executes well.
201.29%
3Y equity/share CAGR of 201.29% while Biotechnology median is zero. Walter Schloss sees a modest short-term advantage that could compound if momentum persists.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
67.39%
We expand assets while Biotechnology is negative. Peter Lynch sees a possible advantage if expansions align with profitable markets or a recovering cycle.
64.49%
Positive BV/share change while Biotechnology median is negative. Peter Lynch finds a strong advantage vs. peers failing to expand equity.
No Data
No Data available this quarter, please select a different quarter.
13.21%
R&D growth far exceeding Biotechnology median. Jim Chanos suspects a potential “throw money at problems” approach or a race for new tech that might not pay off.
-38.56%
SG&A decline while Biotechnology grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.